Zongertinib, also known as BI 1810631, is a highly potent and selective HER2 TKI that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertions (ex20ins), while sparing EGFR. BI 1810631 has demonstrated antitumor activity in patients with non–small cell lung cancer (NSCLC). Compound-mediated reduction of cell growth and survival was observed in mutant HER2 driven Ba/F3 cell systems, in human tumor cell lines in vitro and translated into tumor regressions in a genome-engineered HER2-YVMA mutant xenograft model. The in vivo efficacy of BI 1810631 was further confirmed in HER2 exon 20 mutant patient-derived tumor models.
MedKoo Cat#: 130071
Name: Zongertinib
CAS#: 2728667-27-2
Chemical Formula: C29H29N9O2
Exact Mass: 535.2444
Molecular Weight: 535.61
Elemental Analysis: C, 65.03; H, 5.46; N, 23.54; O, 5.97
The following data is based on the product molecular weight 535.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
